Clinical Trial

The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment. Immune reconstitution (IR) is critical for improving HSCT efficacy and quality of life among survivors, yet its dynamic impact on survival and complications like chronic graft-versus-host disease (cGVHD) in CMML is poorly defined. This study aimed to investigate the dynamics of IR following HSCT in patients with CMML and evaluate its impact on post-transplant clinical outcomes.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-02.
Trial Details
NCT Number NCT07113730
Lead Sponsor Peking University People's Hospital
Collaborators: The First Hospital of Jilin University, 960th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions Chronic Myelomonocytic Leukemia (CMML), Immune Reconstitution
Enrollment 300 participants
Start Date 2025-08-13
Primary Completion 2035-07-31 (estimated)
Study Completion 2036-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-15